Associated Papers
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
Benesova A et al.
American Journal of Hematology, 2024
Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia.
Langabeer SE et al.
Experimental Oncology, 2019
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.
Parker WT et al.
Blood, 2012
Select a paper to view details